Pulmonary hypertension (PH) patients typically present with a diminished platelet count, but the role of platelets in the development and progression of PH remains unclear. Our research has uncovered that within animal models of PH, platelet depletion or transfusion of platelets from healthy donors reduced pulmonary vascular thickening. In contrast, the transfusion of platelets from PH-affected subjects into healthy animals led to an augmentation of pulmonary vascular thickening. Transcriptomic analysis revealed that platelets from PH patients exhibited an upregulation of genes associated with cellular adhesion, platelet activation, and adhesion. Notably, the hub genes, glycoprotein IIb/IIIa (GP IIb/IIIa), were implicated in mediating platelet-endothelium adhesion through their interaction with intercellular adhesion molecule-1 (ICAM-1) on pulmonary arterial endothelial cells, triggering platelet activation and the subsequent release of platelet-derived growth factor BB (PDGF-BB). This release increased the proliferation and migration of pulmonary arterial smooth muscle cells (PASMCs). The pharmacological targeting of ICAM-1 has been shown to mitigate PH in a murine model under hypoxic conditions; however, this ameliorative effect was not observed in thrombocytopenic mice under analogous conditions. In summary, the adhesion of platelets to the endothelium, facilitated by GP IIb/IIIa and ICAM-1, exacerbates PH by intensifying the thickening of the pulmonary vascular wall through platelet activation and PDGF-BB secretion.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1165/rcmb.2024-0438OC | DOI Listing |
Am J Med
March 2025
Alzheimer Scotland Centre for Policy and Practice, University of the West of Scotland, Paisley, UK.
Eur J Intern Med
March 2025
INSERM, U1059, SAINBIOSE, Jean Monnet University, 42023, Saint-Etienne, France; Therapeutic and Vascular Medicine Department, University Hospital of Saint-Etienne, 42270, Saint-Etienne, France; INSERM, CIC 1408, 42023, Saint-Etienne, France.
J Am Coll Cardiol
March 2025
Cedars Sinai Medical Center, Los Angeles, California, USA. Electronic address:
This updated Heart Valve Collaboratory framework addresses the growing concern for transcatheter valve failure (TVF) following transcatheter aortic valve replacement (TAVR). With the increasing volume of redo-TAV and surgical TAV explantation, there is a critical need for standardized pathways and protocols for evaluating TVF using echocardiography and cardiac computed tomography (CT) angiography. This document clarifies prior definitions of bioprosthetic valve deterioration and bioprosthetic valve failure in a practical, imaging directed context for TAVR.
View Article and Find Full Text PDFLife Sci
March 2025
Department of Physiology, Hebei Medical University, 050017, Hebei, China; The Key Laboratory of Neural and Vascular Biology, Ministry of Education, 050017, Hebei, China; Hebei Key Laboratory of Cardiovascular Homeostasis and Aging, 050017, Hebei, China. Electronic address:
Aims: The present study aimed to investigate the direct link between trimethylamine N-oxide (TMAO) and diastolic dysfunction in heart failure with preserved ejection fraction (HFpEF).
Materials And Methods: Diastolic dysfunction is the main manifestation of HFpEF, so the "two-hit" mouse HFpEF model are used. After treated with high-fat diet (HFD) and N-nitro-l-arginine methyl ester (L-NAME) for 8 weeks, the cardiac function, myocardial fibrosis, oxidative stress levels, and molecular alterations were assessed.
J Pharmacol Exp Ther
February 2025
Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Pulmonary fibrosis encompasses different chronic interstitial lung diseases, and the predominant form, idiopathic pulmonary fibrosis, remains to have a poor prognosis despite 2 approved therapies. Although the exact pathobiological mechanisms are still incompletely understood, epithelial injury and aberrant wound healing responses contribute to the gradual change in lung architecture and functional impairment. Lysophosphatidic acid (LPA)-induced lysophosphatidic receptor 1 (LPA1) signaling was proposed to be a driver of lung fibrosis, and LPA1 antagonists have shown promising antifibrotic profiles in early clinical development.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!